Advanced search×

Pulmonary nocardiosis developed in a hematopoietic stem cell transplant recipient with bronchiolitis obliterans.

Intern Med 49(14):1441-4 (2010) PMID 20647664

The chronic graft-versus-host disease often requires unceasing immunosuppressive therapy (IST), which increases a risk of infectious complications in hematopoietic stem cell transplantation (HSCT) recipients. We report an adult T-cell leukemia/lymphoma case who developed pulmonary nocardiosis, a rare pulmonary complication, after allogeneic HSCT despite administration of the prophylactic trimethoprim-sulfamethoxazole (TMP/STX). The inhaled corticosteroid in addition to systemic IST had been started for bronchiolitis obliterance 4 months prior to nocardiosis development. The patient was successfully treated with an increased dose of TMP/STX combined with meropenem. Transplantation physicians should keep this rare pulmonary complication in mind during sustained IST.

Version: za2963e q8zab q8zb5 q8zc4 q8zd8 q8zef q8zf2 q8zg4

Similar articles you may find interesting…

  1. Generation of Lung Epithelium from Pluripotent Stem Cells.

    Current Pathobiology Reports 1(2):137-145 (2013) PMID 23662247

    We discuss the recent advances in the generation of respiratory epithelia from pluripotent stem cells and the potential of these engineered cells for novel scientific discoveries in lung diseases and future translation into regenerative therapies....
  2. The metastatic microenvironment: Lung-derived factors control the viability of neuroblastoma lung metastasis.

    Int J Cancer (2013) PMID 23649556

    We were able to generate two neuroblastoma cell populations - lung micrometastatic (MicroNB) cells and lung macrometastatic (MacroNB) cells. These two types of cells share the same genetic background, invade the same distant organ, but differ in their ability to create metastasis in the lungs. We hy...
  3. Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients.

    Infection (2013) PMID 23653428

    Treatment with intravenous colistin, with dosage adjusted to renal function, was relatively safe for HM/HSCT patients, even with concomitantly administered nephrotoxic medications. Concern about nephrotoxicity should not justify a delay in initiating empirical colistin treatment in situations where...